BPC
NRIX icon

Bryce Point Capital’s Nurix Therapeutics NRIX Stock Holding History

Bryce Point Capital’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-28,564
Closed -$538K – 364
2024
Q4 		$538K Buy
+28,564
New +$655K 0.16% 214

Other funds holding NRIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bryce Point Capital's NRIX Position: Q1 2025 in Review

Bryce Point Capital sold out of Nurix Therapeutics (NRIX) in Q1 2025, closing a stake of 28,564 shares — an estimated $538K sold.

Bryce Point Capital first reported a position in NRIX in Q4 2024 and held it in 1 quarter. The position peaked at $538K in Q4 2024. 170 funds tracked by Wall St. Rank hold NRIX as of Q1 2025.

  • Bryce Point Capital reported no remaining Nurix Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bryce Point Capital sold 28,564 Nurix Therapeutics shares in Q1 2025, an estimated $538K.
  • Bryce Point Capital first reported a position in Nurix Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bryce Point Capital's Nurix Therapeutics position peaked at $538K in Q4 2024.
  • 170 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2025.

Based on Bryce Point Capital's 13F filing for Q1 2025, filed 7 May 2025.